Absorption kinetics of 5-aminosalicylic acid in rat: Influence of indomethacin-induced gastrointestinal lesions and Escherichia Coli Nissle 1917 medication

Neuroendocrinology Letters

Volumn 32, Issue SUPPL. 1, 2011, Pages 46-52

  Kuneš, Martin ^a   Květina, Jaroslav ^a   Kholová, Dagmar ^a   Bureš, Jan ^b   Tláskalová Hogenová, Helena ^c   Pavlík, Michal ^d  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^d UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

5 aminosalicylic acid; Escherichia Coli Nissle 1917; Experimental pigs; Indomethacin; Pharmacokinetics

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; INDOMETACIN; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG ADSORPTION; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

EID: 84857393103     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Alexopoulos C, Georgoulakis IE, Tzivara A, Kyriakis CS, Govaris A, Kyriakis SC (2004) Field evaluation of the effect of a probiotic-containing Bacillus licheniformis and Bacillus subtilis spores on the health status, performance, and carcass quality of grower and finisher pigs. J Vet Med A Physiol Pathol Clin Med. 51: 306-12. (Pubitemid 41695275)
2. Blum G, Marre R, Hacker J (1995) Properties of Escherichia coli strains of serotype O6. Infection. 23: 234-236.
3. Blum-Oehler G, Oswald S, Eiteljörge K, Sonnenborn U, Schulze J, Kruis W, et al (2003) Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol. 154: 59-66. (Pubitemid 36165168)
4. Bures J, Pejchal J, Kvetina J, Tichy A, Rejchrt S, Kunes M, et al (2011a) Morphometric analysis of the porcine gastrointestinal tract in a 10-day high-dose Indomethacin administration with or without probiotic bacteria Escherichia coli Nissle 1917. Hum Exp Toxicol. [PubMed - as supplied by publisher]
5. Bures J, Smajs D, Kvetina J, Förstl M, Smarda J, Kohoutova D, et al (2011b) Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle. World J Gastroenterol. 17: 609-617.
6. Council of Europe (1986) Explanatory Report on the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. Strasbourg
7. Del Soldato P, Foschi D, Benoni G, Scarpignato C (1985) Oxygen free radicals interact with indomethacin to cause gastrointestinal injury. Agents Actions. 17: 484-488.
8. Duncker SC, Lorentz A, Schroeder B, Breves G, Bischoff SC (2006) Effect of orally administered probiotic E. coli strain Nissle 1917 on intestinal mucosal immune cells of healthy young pigs. Vet Immunol Immunopathol. 111: 239-50.
9. Ettarh RR, Carr KE (1996) Morphometric analysis of the small intestinal epithelium in the indomethacin-treated mouse. J Anat. 189: 51-56. (Pubitemid 26280534)
10. Ettarh RR, Carr KE (1993) Structural and morphometric analysis of murine small intestine after indomethacin administration. Scand J Gastroenterol. 28: 795-802. (Pubitemid 23274889)
11. Fric P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in smptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 15: 313-315. (Pubitemid 36337852)
12. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M (2002) Treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther. 16 (Suppl 4): 13-9. (Pubitemid 34595612)
13. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al (2000) Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 119: 305-309. (Pubitemid 30621980)
14. Goerg KJ, Schlorer E (1998) Probiotic therapy of pseudomembranous colitis. Combination of intestinal lavage and oral administration of Escherichia coli. Dtsch Med Wochenschr. 123: 1274-1278. (Pubitemid 28502843)
15. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, et al (2006) Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun. 74: 4075-4082. (Pubitemid 43993340)
16. Greenberg GR (2004) Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis. 10: 318-320.
17. Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, et al (2004) Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol. 186: 5432-5441. (Pubitemid 39038145)
18. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, et al (2002) A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol. 184: 5912-5925. (Pubitemid 35168240)
19. Hawkey CJ, Langmann MJ (2003) Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 52: 600-608. (Pubitemid 36363420)
20. Heeba GH, Hassan MKA, Amin RS (2009) Gastroprotective effect of simvastatin against indomethacin-induced gastric ulcer in rats: Role of nitric oxide and prostaglandins. Eur J Pharmacol 607: 188-193.
21. Helwig U, Lammers KM, Rizzello F, Brigidi P, Rohleder V, Caramelli E, et al (2006) Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol. 12: 5978-5986. (Pubitemid 44608476)
22. Hoffmann CJ, Zeitz M, Bischoff SC (2004) Diagnosis and therapy of ulcerative colitis results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network of inflammatory bowel disease. Z Gastroenterol. 42: 979-983. (Pubitemid 39625605)
23. Kalliomäki M, Salminen S, Arvilomni H, Kero P, Koskinen P, Isolauri E (2001) Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 361: 1076-1079. (Pubitemid 32322538)
24. Kalliomäki M, Salminen S, Poussa T, Arvilomni H, Isolauri E (2003) Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 361: 1869-1871. (Pubitemid 36645184)
25. Kamil R, Geier MS, Bulter RN, Howarth GS (2007) Lactobacillus rhamnosus GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy. Dig Dis Sci. 52: 1247-1252. (Pubitemid 46626177)
26. Kim J-H, Kim B-W, Kwon H-J, Nam S-W (2011) Curative effect of selenium against indomethacin-induced gastric ulcers in rats. J Microbiol Biotechnol 21: 400-404.
27. Krammer HJ, Kämper H, von Bünau R, Zieseniss E, Stange C, Schlieger F, et al (2006) Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients. Z Gastroenterol. 44: 651-656. (Pubitemid 44385516)
28. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 53: 1617-1623. (Pubitemid 39434105)
29. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaing remission of ulcerative colitis. Aliment Pharmacol Ther. 11: 853-858.
30. Kunes M, Kvetina J, Bures J (2009) Type and distribution of indomethacin-induced lesions in the gastrointestinal tract of rat. Neuro Endocrinol Lett. 30 (Suppl 1): 96-100.
31. Kunes M, Kvetina J, Svoboda Z, Herout V (2005) Study of the mechanisms of intestinal absorption of xenobiotics using in situ perfusion of rat intestine. Biologia. 60 (Suppl 17): 89-92. (Pubitemid 44804873)
32. Kuzela I, Kascak M, Vavrecka A (2001) Induction and maintenance of remission with nonpathogenic Escherichia coli in patiens with pouchitis. Am J Gastroenterol. 96: 3218-3219. (Pubitemid 33095379)
33. Kvetina J, Kunes M, Bures J, Kopácová M, Tachecí I, Spelda S et al (2008) The use of wireless capsule enteroscopy in a preclinical study: a novel diagnostic tool for indomethacin-induced gastrointestinal injury in experimental pigs. Neuroendocrinol Lett. 29: 763-769.
34. Květina J, Parǐzek J (1966) Changes in some biochemical properties of the intestines in the course of acute postirradiation disease. Sb Ved Pr Lek Fak Karlovy Univerzity Hradec Kralove. 9: 659-666.
35. Lammers KM, Vergopoulos A, Babel N, Gionchetti P, Rizzello F, Morselli C, et al (2005) Probiotic therapy in the prevention of pouchitis onset: decreased interleukin-1beta, interleukin-8, and interferon-gamma gene expression. Bowel Dis. 11: 447-454. (Pubitemid 40704079)
36. Loew D (2000) Leben und Werken von Alfred Nissle. 11-19.
37. Mach T (2006) Clinical usefulness of probiotics in inflammatory bowel diseases. J Physiol Pharmacol. 57 (Suppl 9): 23-33.
38. Malchow HA (1997) Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 25: 653-658.
39. McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. (1995) Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol. 90: 439-448.
40. Mehrabani D, Rezaee A, Azarpira N, Fattahi MR, Amini M, Tanideh N, et al (2009) The healing effects of Teucrium polium in the repair of indomethacin-induced gastric ulcer in rats. Saudi Med J. 30: 494-499.
41. Nobilis M, Vybíralová Z, Sládková K, Lísa M, Holcapek M, Kvetina J (2006) High-performance liquid-chromatographic determination of 5-aminosalicylic acid and its metabolites in blood plasma. J Chromatogr A. 1119: 299-308. (Pubitemid 43831900)
42. Odabasoglu F, Cakir A, Suleyman H, Asian A, Bayir Y, Halici M, et al (2006) Gastroprotective and antioxidant effects of usnic acid on indomethacin-induced gastric ulcer in rats. J Ethnopharmacol. 103: 59-65. (Pubitemid 41681142)
43. Otte MJ, Podolsky DK (2004) Functional modulation of enterocytes by Gram-positive and Gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol. 286: G613-626.
44. Rainsford KD, Stetsko PI, Sirko SP, Debski S (2003) Gastrointestinal mucosal injury following repeated daily oral administration of conventional formulations of indomethacin and other non-steroidal anti-inflammatory drugs to pigs: a model for human gastrointestinal disease. J Pharm Pharmacol. 55: 661-668.
45. Rembacken BJ, Spelling AM, Hawkey PM, Chalmers DM, Axon AT (1999) Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354: 635-639. (Pubitemid 29391428)
46. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 126: 1620-1633.
47. Schroeder B, Duncker S, Barth S, Bauerfeind R, Gruber AD, Deppenmeier S, et al (2006) Preventive effects of the probiotic Escherichia coli strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. Dig Dis Sci. 51: 724-731.
48. Schultz MJ, Scholmerich J, Rath HC (2003) Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis. 21: 105-128. (Pubitemid 37323490)
49. Sturm A, Rilling K, Baumgart DC, Gargas K, Abou-Ghazalé T, Raupach B, et al (2005) Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect Immun. 73: 1452-1465. (Pubitemid 40470731)
50. Suleyman H, Albayrak A, Bilici M, Cadirci E, Halici Z (2010) Different mechanisms in formation and prevention indomethacin-induced gastric ulcers. Inflammation. 33: 224-234.
51. Sun J, Gunzer F, Westendorf AM, Buer J, Scharfe M, Jarek M, et al (2005) Genomic peculiarity of coding sequences and metabolic potential of probiotic Escherichia coli strain Nissle 1917 inferred from raw genome data. J Biotechnol. 117: 147-161. (Pubitemid 40488705)
52. Tachecí I, Kopácová M, Rejchrt S, Bures J (2010) Non-steroidal anti-inflammatory drug induced injury to the small intestine. Acta Medica. 53: 3-11.
53. Takeuchi K, Ueshima K, Hironaka Y, Fujioka Y, Matsumoto J, Okabe S (1991) Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Relation to gastric hypermotility. Digestion. 49: 175-184.
54. Tromm A, Niewerth U, Khoury M, Baestlein E, Wilhelms G, Schulze J et al (2004) The probiotic E. coli strain Nissle 1917 for the treatment of collagenous colitis: first results of an open-label trial. Z Gastroenterol. 42: 365-369. (Pubitemid 38720390)
55. Vaananen PM, Meddings JB, Wallace JL (1991) Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol. 261: G470-G475.
56. Vanbelle M, Teller E, Focant M (1990) Probiotics in animal nutrition: a review. Arch Tierernähr. 40: 543-567.
57. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, et al (2005) Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. Immunol Med Microbiol. 43: 373-384. (Pubitemid 40228949)